- Home
- ACIC vs ZURA Comparison
ACIC vs ZURA Comparison
Compare ACIC & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACIC | ZURA |
|---|---|---|
| Founded | 1999 | 2022 |
| Country | United States | United States |
| Employees | N/A | 30 |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 554.5M | 521.8M |
| IPO Year | 2007 | N/A |
Fundamental Metrics
Financial Performance| Metric | ACIC | ZURA |
|---|---|---|
| Price | $11.60 | $5.36 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 6 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 142.8K | ★ 603.2K |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | ★ 6.33% | N/A |
| EPS Growth | ★ 39.61 | N/A |
| EPS | ★ 2.15 | N/A |
| Revenue | ★ $335,439,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.00 | N/A |
| P/E Ratio | $5.51 | ★ N/A |
| Revenue Growth | ★ 13.07 | N/A |
| 52 Week Low | $9.97 | $0.99 |
| 52 Week High | $13.06 | $7.25 |
Technical Indicators
Market Signals| Indicator | ACIC | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 47.41 | 44.95 |
| Support Level | $11.53 | $5.28 |
| Resistance Level | $11.77 | $5.82 |
| Average True Range (ATR) | 0.21 | 0.35 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 1.41 | 46.97 |
Price Performance
Historical ComparisonAbout ACIC American Coastal Insurance Corporation
American Coastal Insurance Corp is a holding company that underwrites commercial residential property and casualty insurance policies in the United States through its wholly-owned insurance subsidiary.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.